As a Principal, Matthew provides strategic counsel to a variety of clients across the life sciences industry. His experience spans a range of therapeutic areas, including oncology, immunology, rare disease, neurology, and infectious disease. He has particular interest working in genetic medicines and other advanced therapies, both in shaping the platform strategy of early-stage companies with innovative technologies and helping to guide larger companies as they determine how to invest in these areas.
Prior to joining ClearView, Matthew received his Ph.D. in Cancer and Stem Cell Biology at the New York University School of Medicine, where his research focused on the role of Wnt signaling and other key signal transduction pathways in tumorigenesis and stem cell maintenance. He received a B.S. in Biological Sciences from Cornell University.
Debbi Amanti Belanger
Vini De Nadai